Orally disintegrating selegiline (Zelapar) ( DrugBank: Selegiline )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00443872 (ClinicalTrials.gov)	March 2007	3/3/2007	Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects Wi ...	Adding Orally Disintegrating Selegiline (Zelapar)to Patients Taking Dopamine Agonists and Experienci ...	Parkinson's Disease	Drug: orally disintegrating selegiline (Zelapar)	Parkinson's Disease and Movement Disorder Center of Boca Raton	Valeant Pharmaceuticals International, Inc.	Completed	30 Years	90 Years	All	77	Phase 4	United States
2	NCT00640159 (ClinicalTrials.gov)	January 2007	18/3/2008	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapa ...	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapa ...	Parkinson's Disease	Drug: Zelapar	Baylor College of Medicine	NULL	Completed	30 Years	90 Years	Both	55	Phase 4	United States

First Previous1Next Last